About this book:

*Celgene Corp.: The Story of an American Company* charts the remarkable journey of Celgene, a biopharmaceutical company that defied conventional wisdom to become a global leader in oncology and immunology. Beginning as a modest spin-off from a chemical company in 1986, Celgene embarked on an audacious path, most notably by re-evaluating thalidomide—a drug infamous for its devastating past—and transforming it into a life-saving therapy for multiple myeloma and other severe conditions. This book delves into the scientific breakthroughs that underpinned its flagship products like Thalomid, Revlimid, and Pomalyst, showcasing Celgene’s relentless commitment to innovation and its willingness to embrace high-risk, high-reward research.

Beyond its groundbreaking drug development, the book explores the strategic decisions that fueled Celgene's meteoric financial rise, from its first profit in 2003 to multi-billion-dollar revenues, largely driven by Revlimid's blockbuster success. It details the company's aggressive R&D investment, often double the industry average, and its astute M&A strategy, including the transformative acquisitions of Abraxis BioScience for Abraxane, Pharmion for Vidaza, and Juno Therapeutics for cutting-edge cellular immunotherapies. *Celgene Corp.* also examines the complex legal and regulatory battles the company faced, from defending its patents against generic challenges to navigating allegations of improper drug promotion, all while maintaining a strong commitment to corporate social responsibility, patient access, and a diverse workplace culture. The narrative culminates in Celgene's landmark $74 billion acquisition by Bristol Myers Squibb, an event that marked the end of its independent journey but cemented its enduring legacy in modern medicine through its integrated products and pioneering scientific approaches.

What You'll Find Inside:

• **From Chemical Spin-off to Biotech Leader:** Discover how Celgene transformed from a niche chemical unit focused on bioremediation into a global biopharmaceutical giant, exemplifying strategic pivots and audacious risk-taking.
• **The Controversial Comeback of Thalidomide:** Learn how Celgene resurrected thalidomide, a drug infamous for its past, meticulously reintroducing it with stringent safety protocols to revolutionize treatments for multiple myeloma and other conditions.
• **Revlimid's Blockbuster Impact:** Explore the development and meteoric rise of Revlimid, Celgene's flagship immunomodulatory drug (IMiD), which became a multi-billion dollar therapy and cornerstone for multiple myeloma treatment, fueling the company's unprecedented growth.
• **Strategic Growth Through Acquisition and Diversification:** Understand how Celgene rapidly expanded its product portfolio and pipeline through aggressive acquisitions (e.g., Abraxane, Vidaza, CAR T therapies) and diversified into immunology with drugs like Otezla, reducing reliance on a single therapeutic class.
• **A Culture of Innovation and Patient-Centricity:** Uncover the core cultural elements—unwavering R&D commitment, entrepreneurial spirit, and a deep focus on patient needs—that drove Celgene's scientific excellence and its willingness to tackle high-risk, high-reward endeavors.

Who's It For:

This book is ideal for aspiring and current professionals in the biotechnology and pharmaceutical industries, including scientists, researchers, business development managers, and investors, who wish to understand the dynamics of innovation, strategic growth, and regulatory navigation in biopharma. It also appeals to business students, healthcare policy analysts, and anyone interested in the intersection of science, commerce, and patient care, offering a detailed case study of a company that profoundly impacted modern medicine.